Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 19, 2025
Subject: Regulatory approval of Blenrep (belantamab mafodotin) combinations in Japan for the treatment of relapsed/refractory multiple myeloma.
Key Financial Metrics
This filing is a regulatory announcement regarding clinical trial results and product approval. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Clinical Results
The filing details the approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations, marking the second major global approval following the UK's MHRA authorization in April 2025. Key clinical data supporting this approval includes:
- DREAMM-7 Trial (Blenrep + Bortezomib + Dexamethasone vs. Daratumumab + Bortezomib + Dexamethasone):
- Median Progression-Free Survival (PFS): 36.6 months vs. 13.4 months (HR: 0.41).
- Overall Survival (OS): 42% reduction in risk of death (HR: 0.58); 3-year OS rate was 74% vs. 60%.
- DREAMM-8 Trial (Blenrep + Pomalidomide + Dexamethasone vs. Bortezomib + Pomalidomide + Dexamethasone):
- Median PFS: Not yet reached vs. 12.7 months (HR: 0.52).
- 1-Year PFS Rate: 71% vs. 51%.
- OS trend was positive but not statistically significant at interim analysis (HR: 0.77).
- Safety Profile: Eye-related side effects were managed with dose adjustments; discontinuation rates were ≤9%. No confirmed cases of permanent bilateral vision loss. Common non-ocular adverse events included thrombocytopenia, neutropenia, and diarrhea.
Guidance, Outlook, and Risks
Regulatory Outlook:
- United States: Under FDA review with a Prescription Drug User Fee Act (PDUFA) date of July 23, 2025.
- European Union: Under review by the European Medicines Agency.
- China: Under priority review with Breakthrough Therapy Designation.
- Canada & Switzerland: Under priority review.
Management Commentary: GSK management states that Blenrep combinations have the potential to redefine treatment outcomes for patients at or after first relapse, offering superior efficacy and the advantage of in-office administration without complex pre-administration regimens.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in GSK's 2024 Form 20-F and Q1 2025 results. Specific risks include the potential for regulatory delays in other markets and the management of ocular adverse events.
Investor Verification Checklist
- Verify the July 23, 2025, PDUFA decision date for US FDA approval.
- Monitor the final Overall Survival (OS) data for the DREAMM-8 trial, which was not statistically significant at interim analysis.
- Review the updated Product Information (PI) in Japan for specific dosage and safety precautions.
- Assess the commercial launch timeline in Japan following the MHLW approval.
- Track the status of priority reviews in China, Canada, and Switzerland.